{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T18:22:52Z","timestamp":1789928572272,"version":"4.0.1"},"reference-count":67,"publisher":"Elsevier BV","issue":"7-8","license":[{"start":{"date-parts":[[2007,7,1]],"date-time":"2007-07-01T00:00:00Z","timestamp":1183248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2007,7]]},"DOI":"10.1016\/j.lpm.2007.01.006","type":"journal-article","created":{"date-parts":[[2008,1,26]],"date-time":"2008-01-26T05:54:08Z","timestamp":1201326848000},"page":"1084-1097","source":"Crossref","is-referenced-by-count":15,"title":["Maladie de\u00a0Fabry: propositions d'ungroupe d'experts fran\u00e7ais concernant le\u00a0diagnostic, le\u00a0traitement et\u00a0le\u00a0suivi des\u00a0patients"],"prefix":"10.1016","volume":"36","author":[{"given":"Olivier","family":"Lidove","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumeya","family":"Bekri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyril","family":"Goizet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Khau Van Kien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9lim","family":"Aractingi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Knebelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Choukroun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Tsimaratos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Redonnet-Vernhet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Lacombe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Jaussaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lpm.2007.01.006_bib1","series-title":"The Metabolic and Molecular Bases of Inherited Diseases, 8th ed","first-page":"3733","article-title":"a galactosidase A deficiency: Fabry disease","author":"Desnick","year":"2001"},{"key":"10.1016\/j.lpm.2007.01.006_bib2","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1136\/jmg.38.11.750","article-title":"Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males","volume":"38","author":"MacDermot","year":"2001","journal-title":"J Med Genet"},{"key":"10.1016\/j.lpm.2007.01.006_bib3","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/jmg.38.11.769","article-title":"Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females","volume":"38","author":"MacDermot","year":"2001","journal-title":"J Med Genet"},{"key":"10.1016\/j.lpm.2007.01.006_bib4","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/00005792-200203000-00003","article-title":"Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course","volume":"81","author":"Branton","year":"2002","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.lpm.2007.01.006_bib5","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","article-title":"Prevalence of lysosomal storage disorders","volume":"281","author":"Meikle","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.lpm.2007.01.006_bib6","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJM199508033330504","article-title":"An atypical variant of Fabry's disease in men with left ventricular hypertrophy","volume":"333","author":"Nakao","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2007.01.006_bib7","unstructured":"European Public Assessment Report for Replagal. London: European Agency for the Evaluation of Medicinal Products, 2001 http:\/\/www.eudra.org\/humandocs\/Humans\/EPAR\/replagal\/replagal.htm."},{"key":"10.1016\/j.lpm.2007.01.006_bib8","unstructured":"European Public Assessment Report for Fabrazyme. London: European Agency for the Evaluation of Medicinal Products, 2001. http:\/\/www.eudra.org\/humandocs\/Humans\/EPAR\/fabrazyme\/fabrazyme.htm."},{"key":"10.1016\/j.lpm.2007.01.006_bib9","unstructured":"www.dh.gov.uk\/assetRoot\/04\/11\/84\/08\/04118408.pdf."},{"key":"10.1016\/j.lpm.2007.01.006_bib10","unstructured":"http:\/\/iier.isciii.es\/er\/rec\/er_973a.pdf."},{"key":"10.1016\/j.lpm.2007.01.006_bib11","unstructured":"www.health.gov.au\/internet\/wcms\/publishing.nsf\/Content\/health-pbs-general-supply-othersupply-copy2\/$FILE\/fabryguide.pdf."},{"key":"10.1016\/j.lpm.2007.01.006_bib12","first-page":"2407","article-title":"Fabry\u2019s disease, recommendation for diagnostics, follow up and treatment in Finland","volume":"120","author":"Penttinen","year":"2004","journal-title":"Duodecim"},{"key":"10.1016\/j.lpm.2007.01.006_bib13","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1016\/S0272-6386(04)01094-7","article-title":"A novel alpha-galactosidase a mutant (M42L) identified in a renal variant of Fabry disease","volume":"44","author":"Rosenthal","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.lpm.2007.01.006_bib14","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2165\/00128071-200304030-00005","article-title":"Fabry disease: recognition and management of cutaneous manifestations","volume":"4","author":"Mohrenschlager","year":"2003","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.lpm.2007.01.006_bib15","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/j.1742-1241.2006.01061.x","article-title":"Hyperhidrosis: a new and often early symptom in Fabry disease. International experience and data from FOS \u2013 the Fabry Outcome Survey","volume":"60","author":"Lidove","year":"2006","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.lpm.2007.01.006_bib16","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/00004728-200403000-00002","article-title":"Fabry disease: renal sonographic and magnetic resonance imaging findings in affected males and carrier females with classic and cardiac variant phenotypes","volume":"28","author":"Glass","year":"2004","journal-title":"J Comput Assist Tomogr"},{"key":"10.1016\/j.lpm.2007.01.006_bib17","first-page":"355","article-title":"C\u0153ur et maladie de Fabry","volume":"2","author":"Lidove","year":"2006","journal-title":"Med Th\u00e9rap"},{"key":"10.1016\/j.lpm.2007.01.006_bib18","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/ana.410400105","article-title":"Cerebrovascular complications of Fabry\u2019s disease","volume":"40","author":"Mitsias","year":"1996","journal-title":"Ann Neurol"},{"key":"10.1016\/j.lpm.2007.01.006_bib19","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2190\/JKFW-3WXK-QA7N-BYLN","article-title":"Psychiatric disorders in patients with Fabry\u2019s disease","volume":"23","author":"Grewal","year":"1993","journal-title":"Int J Psychiatry Med"},{"key":"10.1016\/j.lpm.2007.01.006_bib20","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1471-2350-3-10","article-title":"Patients affected with Fabry disease have an increased incidence of progressive hearing loss and sudden deafness: an investigation of twenty-two hemizygous male patients","volume":"3","author":"Germain","year":"2002","journal-title":"BMC Med Genet"},{"key":"10.1016\/j.lpm.2007.01.006_bib21","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1023\/B:BOLI.0000009948.86528.72","article-title":"Hearing loss in Fabry disease: the effect of agalsidase alfa replacement therapy","volume":"26","author":"Hajioff","year":"2003","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.lpm.2007.01.006_bib22","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1164\/ajrccm.155.3.9116979","article-title":"Pulmonary involvement in Fabry disease","volume":"155","author":"Brown","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.lpm.2007.01.006_bib23","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1023\/A:1015511908710","article-title":"Quality of life of patients with Fabry disease","volume":"11","author":"Gold","year":"2002","journal-title":"Qual Life Res"},{"key":"10.1016\/j.lpm.2007.01.006_bib24","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1023\/A:1015009210639","article-title":"Assessment of health-related quality-of-life in males with Anderson Fabry Disease before therapeutic intervention","volume":"11","author":"Miners","year":"2002","journal-title":"Qual Life Res"},{"key":"10.1016\/j.lpm.2007.01.006_bib25","first-page":"157","article-title":"Fabry\u2019s disease: enzymatic diagnosis of hemizygotes and heterozygotes. Alpha-galactosidase activities in plasma, serum, urine, and leukocytes","volume":"81","author":"Desnick","year":"1973","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.lpm.2007.01.006_bib26","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/humu.20144","article-title":"Detection of alpha-galactosidase A mutations causing fabry disease by denaturing high performance liquid chromatography","volume":"25","author":"Shabbeer","year":"2005","journal-title":"Hum Mutat"},{"key":"10.1016\/j.lpm.2007.01.006_bib27","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s004390051066","article-title":"A comparison of BRCA1 mutation analysis by direct sequencing, SSCP and DHPLC","volume":"105","author":"Gross","year":"1999","journal-title":"Hum Genet"},{"key":"10.1016\/j.lpm.2007.01.006_bib28","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1046\/j.1469-1809.1999.6350383.x","article-title":"Superiority of denaturing high performance liquid chromatography over single-stranded conformation and conformation-sensitive gel electrophoresis for mutation detection in TSC2","volume":"63","author":"Choy","year":"1999","journal-title":"Ann Hum Genet"},{"key":"10.1016\/j.lpm.2007.01.006_bib29","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/humu.9172","article-title":"Molecular analysis in Fabry disease in Spain: fifteen novel GLA mutations and identification of a homozygous female","volume":"22","author":"Rodriguez-Mari","year":"2003","journal-title":"Hum Mutat"},{"key":"10.1016\/j.lpm.2007.01.006_bib30","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1186\/1479-7364-2-5-297","article-title":"Fabry disease: Identification of 50 novel alpha-galactosidase A mutations causing the classic phenotype and three-dimensional structural analysis of 29 missense mutations","volume":"2","author":"Shabbeer","year":"2006","journal-title":"Hum Genomics"},{"key":"10.1016\/j.lpm.2007.01.006_bib31","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1006\/abio.1998.2966","article-title":"Quantitative determination of globotriaosylceramide by immunodetection of glycolipid-bound recombinant verotoxin B subunit","volume":"267","author":"Zeidner","year":"1999","journal-title":"Anal Biochem"},{"key":"10.1016\/j.lpm.2007.01.006_bib32","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0014-5793(02)02491-2","article-title":"Synthesis of novel internal standards for the quantitative determination of plasma ceramide trihexoside in Fabry disease by tandem mass spectrometry","volume":"515","author":"Mills","year":"2002","journal-title":"FEBS Lett"},{"key":"10.1016\/j.lpm.2007.01.006_bib33","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1373\/clinchem.2004.038323","article-title":"Liquid chromatography-tandem mass spectrometry quantification of globotriaosylceramide in plasma for long-term monitoring of Fabry patients treated with enzyme replacement therapy","volume":"51","author":"Roddy","year":"2005","journal-title":"Clin Chem"},{"key":"10.1016\/j.lpm.2007.01.006_bib34","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1086\/422366","article-title":"Long-term safety and efficacy of enzyme replacement therapy for Fabry disease","volume":"75","author":"Wilcox","year":"2004","journal-title":"Am J Human Genet."},{"key":"10.1016\/j.lpm.2007.01.006_bib35","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/08035320510028111","article-title":"Is globotriaosylceramide a useful biomarker in Fabry disease?","volume":"94","author":"Young","year":"2005","journal-title":"Acta Paediatr Suppl"},{"key":"10.1016\/j.lpm.2007.01.006_bib36","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1373\/clinchem.2004.041418","article-title":"Urinary lipid profiling for the identification of fabry hemizygotes and heterozygotes","volume":"51","author":"Fuller","year":"2005","journal-title":"Clin Chem"},{"key":"10.1016\/j.lpm.2007.01.006_bib37","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ymgme.2005.01.007","article-title":"Non-invasive screening method for Fabry disease by measuring globotriaosylceramide in whole urine samples using tandem mass spectrometry","volume":"85","author":"Kitagawa","year":"2005","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.lpm.2007.01.006_bib38","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10545-005-5263-4","article-title":"Measurement of urinary CDH and CTH by tandem mass spectrometry in patients hemizygous and heterozygous for Fabry disease","volume":"28","author":"Mills","year":"2005","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.lpm.2007.01.006_bib39","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1136\/jmg.33.8.682","article-title":"Uneven X inactivation in a female monozygotic twin pair with Fabry disease and discordant expression of a novel mutation in the alpha-galactosidase A gene","volume":"33","author":"Redonnet-Vernhet","year":"1996","journal-title":"J Med Genet"},{"key":"10.1016\/j.lpm.2007.01.006_bib40","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00109-005-0656-2","article-title":"Relationship between X-inactivation and clinical involvement in Fabry heterozygotes. Eleven novel mutations in the alpha-galactosidase A gene in the Czech and Slovak population","volume":"83","author":"Dobrovolny","year":"2005","journal-title":"J Mol Med"},{"key":"10.1016\/j.lpm.2007.01.006_bib41","doi-asserted-by":"crossref","first-page":"71s","DOI":"10.1016\/S0929-693X(03)90392-7","article-title":"Faut-il faire des tests pr\u00e9symptomatiques chez l\u2019enfant pour des maladies \u00e0 r\u00e9v\u00e9lation tardive?","volume":"10","author":"Lacombe","year":"2003","journal-title":"Arch Pediatr"},{"key":"10.1016\/j.lpm.2007.01.006_bib42","first-page":"341","article-title":"Attitudes toward carrier testing in minors: A systematic review","volume":"16","author":"Borry","year":"2005","journal-title":"Genet Counsel."},{"key":"10.1016\/j.lpm.2007.01.006_bib43","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/ajmg.a.30533","article-title":"Recurrence of Fabry disease as a result of paternal germline mosaicism for alpha-galactosidase a gene mutation","volume":"134","author":"Dobrovolny","year":"2005","journal-title":"Am J Med Genet"},{"key":"10.1016\/j.lpm.2007.01.006_bib44","first-page":"704","article-title":"La Maladie de Fabry: Traitement du syndrome acrodyniforme par la Carbamazepine","volume":"34","author":"Lenoir","year":"1977","journal-title":"Arch Fran\u00e7 P\u00e9d."},{"key":"10.1016\/j.lpm.2007.01.006_bib45","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1023\/A:1025127723729","article-title":"Use of gabapentin to reduce chronic neuropathic pain in Fabry disease","volume":"26","author":"Ries","year":"2003","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.lpm.2007.01.006_bib46","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1212\/WNL.23.8.871","article-title":"Relief of pain of Fabry\u2019s disease by diphenylhydantoin","volume":"23","author":"Lockman","year":"1973","journal-title":"Neurology"},{"key":"10.1016\/j.lpm.2007.01.006_bib47","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(01)06178-5","article-title":"Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack","volume":"358","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2007.01.006_bib48","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ndt\/11.supp7.4","article-title":"Rare diseases in renal replacement therapy in the ERA-EDTA registry","volume":"11","author":"Tsakiris","year":"1996","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.lpm.2007.01.006_bib49","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1046\/j.1523-1755.2002.00097.x","article-title":"Patients with Fabry disease on dialysis in the United States","volume":"61","author":"Thadhani","year":"2002","journal-title":"Kidnet Int."},{"key":"10.1016\/j.lpm.2007.01.006_bib50","doi-asserted-by":"crossref","first-page":"4211","DOI":"10.1016\/j.transproceed.2005.11.021","article-title":"Kidney transplanatation improves survival and is indicated in Fabry\u2019s disease","volume":"37","author":"Inderbitzin","year":"2005","journal-title":"Transplant Proc"},{"key":"10.1016\/j.lpm.2007.01.006_bib51","unstructured":"http:\/\/www.emea.eu.int\/humandocs\/Humans\/EPAR\/replagal\/replagal.htm."},{"key":"10.1016\/j.lpm.2007.01.006_bib52","unstructured":"http:\/\/www.emea.eu.int\/humandocs\/Humans\/EPAR\/fabrazyme\/fabrazyme.htm."},{"key":"10.1016\/j.lpm.2007.01.006_bib53","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.lpm.2007.01.006_bib54","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human a-galactosidase A replacement therapy in Fabry\u2019s disease","volume":"345","author":"Eng","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2007.01.006_bib55","article-title":"Clinical results of enzyme replacement therapy in Fabry disease: a comprehensive review of literature","author":"Lidove","year":"2006","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.lpm.2007.01.006_bib56","doi-asserted-by":"crossref","first-page":"330","DOI":"10.12968\/bjon.2006.15.6.20681","article-title":"Intravenous enzyme replacement therapy: better in home or hospital?","volume":"15","author":"Milligan","year":"2006","journal-title":"Br J Nurs"},{"key":"10.1016\/j.lpm.2007.01.006_bib57","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s10545-005-0018-9","article-title":"Successful pregnancy outcome in a patient with Fabry disease receiving enzyme replacement therapy with agalsidase alfa","volume":"28","author":"Wendt","year":"2005","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.lpm.2007.01.006_bib58","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1023\/A:1012993305223","article-title":"Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes","volume":"24","author":"Whybra","year":"2001","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.lpm.2007.01.006_bib59","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","article-title":"Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey","volume":"34","author":"Mehta","year":"2004","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.lpm.2007.01.006_bib60","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1136\/jmg.2005.036327","article-title":"Natural history of Fabry disease in females in the Fabry Outcome Survey","volume":"43","author":"Deegan","year":"2006","journal-title":"J Med Genet"},{"key":"10.1016\/j.lpm.2007.01.006_bib61","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/01.md.0000178976.62537.6b","article-title":"The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease","volume":"84","author":"Gupta","year":"2005","journal-title":"Medicine"},{"key":"10.1016\/j.lpm.2007.01.006_bib62","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/ndt\/gfi152","article-title":"Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting","volume":"21","author":"Schiffmann","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.lpm.2007.01.006_bib63","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1038\/sj.ki.5000208","article-title":"Clinical benefit of enzyme replacement therapy in Fabry disease","volume":"69","author":"Breunig","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.lpm.2007.01.006_bib64","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1399-0004.2004.00219.x","article-title":"The Mainz severity score index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy","volume":"65","author":"Whybra","year":"2004","journal-title":"Clin Genet"},{"key":"10.1016\/j.lpm.2007.01.006_bib65","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1111\/j.1523-1755.2004.00924.x","article-title":"Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta","volume":"66","author":"Linthorst","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.lpm.2007.01.006_bib66","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10545-005-4415-x","article-title":"Monitoring enzyme replacement therapy in Fabry disease--role of urine globotriaosylceramide","volume":"28","author":"Whitfield","year":"2005","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.lpm.2007.01.006_bib67","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0755-4982(06)74723-6","article-title":"Maladie de Fabry en 2006: une \u00e9valuation th\u00e9rapeutique tr\u00e8s limit\u00e9e","volume":"35","author":"Lidove","year":"2006","journal-title":"Presse Med"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498207000073?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498207000073?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T07:53:24Z","timestamp":1546329204000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498207000073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7]]},"references-count":67,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2007,7]]}},"alternative-id":["S0755498207000073"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2007.01.006","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2007,7]]}}}